Immuno-Oncology Drugs Market Players Innovate Through Strategic Collaborations To Win – EIN News

There were 1,763 press releases posted in the last 24 hours and 273,537 in the last 365 days.
Immuno-Oncology Drugs Market Report 2022 – Opportunities And Strategies – Global Forecast To 2031
The Business Research Company’s Immuno-Oncology Drugs Market – Opportunities And Strategies – Global Forecast To 2031
LONDON, GREATER LONDON, UK, October 24, 2022 /EINPresswire.com/ — Product innovations through strategic collaborations are contributing to the growth of immuno-oncology drugs market. In January 2021, Boehringer Ingelheim, a Germany based pharmaceutical company collaborated with Enara Bio for an undisclosed amount. This collaboration combines Boehringer Ingelheim’s approach to tackling cancer through pairing leading science with innovative immune-oncology platforms, like oncolytic viruses and cancer vaccines, with Enara Bio’s expertise in cancer antigen identification. Enara Bio is a UK based science-led company targeting the T-cell/cancer-cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Therefore, strategic collaborations are expected to drive the growth of the immuno-oncology drugs market.
The global immuno-oncology drugs market size is expected to grow from $67.88 billion in 2021 to $116.24 billion in 2026 at a rate of 11.4%. The global immuno-oncology drugs market share is then expected to grow at a CAGR of 10.0% from 2026 and reach $186.92 billion in 2031.
Read more on the Global Immuno-Oncology Drugs Market Report
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drugs-market
Drug manufacturers are investing in developing personalized cancer vaccines, and few have reached clinical trial phases. Pharmaceutical companies are combining genetic sequencing and precision medicine to create new drug therapies and cancer treatments that are designed to treat specific patients. DNA vaccines are easy and cost effective to manufacture as compared with other neoantigen vaccine. For instance, in April 2021, Washington University School of Medicine researcher’s in shown that personalized cancer vaccines made using DNA can program the immune system to attack malignant tumors, including breast and pancreatic cancers. The findings also shown that a personalized DNA vaccine coupled with other immunotherapies can generate a robust immune response capable of shrinking breast cancers in mice.
Major players covered in the global immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc., Johnson & Johnson.
TBRC’s immuno-oncology drugs market report is segmented by type into immune checkpoint inhibitors, immune system modulators, other monoclonal antibodies, cancer vaccines, others, by therapeutic application into melanoma, lung cancer, blood cancer, renal cell carcinoma, bladder cancer, other therapeutic application, by end-users into hospitals, clinics, ambulatory surgical centers, others.
Immuno-Oncology Drugs Market 2022 – By Type (Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others), By Therapeutic Application (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application), By End-Users (Hospitals, Clinics, Ambulatory Surgical Centers, Others), And By Region, Opportunities And Strategies – Global Forecast To 2031 is one of a series of new reports from The Business Research Company that provides a immuno-oncology drugs market overview, forecast immuno-oncology drugs market size and growth for the whole market, immuno-oncology drugs market segments, geographies, immuno-oncology drugs market trends, immuno-oncology drugs market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request for a Sample of the Global Immuno-Oncology Drugs Market Report
https://www.thebusinessresearchcompany.com/sample.aspx?id=6389&type=smp
Not what you were looking for? Here is a list of similar reports by The Business Research Company:
Checkpoint Inhibitors Global Market Report 2022 – By Drug (PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell), By Application (Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma), By End-Users (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report
Monoclonal Antibodies (MAbs) Global Market Report 2022 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular), By End-User (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Oncology Drugs Global Market Report 2022 – By Type (Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report
About The Business Research Company?
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Check out our:
TBRC Blog: http://blog.tbrc.info/
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Healthcare Blog: https://healthcareresearchreports.com/
Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn
You just read:

EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™, tries to define some of the boundaries that are reasonable in today’s world. Please see our Editorial Guidelines for more information.

Follow EIN Presswire
© 1995-2022 Newsmatics Inc. dba EIN Presswire All Right Reserved.

source

Add a Comment

Your email address will not be published. Required fields are marked *